Efficient construction of a diabody using a refolding system: Anti-carcinoembryonic antigen recombinant antibody fragment

Journal of Biochemistry

Volumn 132, Issue 6, 2002, Pages 903-909

  Asano, Ryutaro ^a   Kudo, Toshio ^a   Nishimura, Yukihiro ^a   Makabe, Koki ^a   Hayashi, Hiroki ^a,b   Suzuki, Masanori ^b   Tsumoto, Kouhei ^a   Kumagai, Izumi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adoptive immunotherapy; Bispecific diabody; CEA; Inclusion body

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; EPITOPE; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY CD3; RECOMBINANT ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CELL INCLUSION; CELL LINE; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; NONHUMAN; PROTEIN FOLDING; PROTEIN RENATURATION; STOICHIOMETRY;

ESCHERICHIA COLI; VECTORS;

EID: 0036947103     PISSN: 0021924X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.jbchem.a003303     Document Type: Article

References (33)

1. Pluckthun, A. and Pack, P. (1997) New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3, 83-105
2. Hudson, P.J. and Souriau, C. (2001) Recombinant antibodies for cancer diagnosis and therapy. Expert Opin. Biol. Ther. 1, 845-855
3. Carter, P. and Merchant, A.M. (1997) Engineering antibodies for imaging and therapy. Curr. Opin. Biotechnol. 8, 449-454
4. Yokota, T., Milenic, D.E., Whitlow, M., and Schlom, J. (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52, 3402-3408
5. Yazaki, P.J., Wu, A.M., Tsai, S.W., Williams, L.E., Ikler, D.N., Wong, J.Y., Shively, J.E., and Raubitschek, A.A. (2001) Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug. Chem. 12, 220-228
6. Holliger, P., Prospero, T., and Winter, G. (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90, 6444-6448
7. Arndt, M.A., Krauss, J., Kipriyanov, S.M., Pfreundschuh, M., and Little, M. (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin’s tumors. Blood 94, 2562-2568
8. Tsumoto, K., Shinoki, K., Kondo, H., Uchikawa, M., Juji, T., and Kumagai, I. (1998) Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent - application to a human single-chain Fv fragment. J. Immunol. Methods 219, 119-129
9. Asano, R., Takemura, S., Tsumoto, K., Sakurai, N., Teramae, A., Ebara, S., Katayose, Y., Shinoda, M., Suzuki, M., Imai, K., Matsuno, S., Kudo, T., and Kumagai, I. (2000) Functional construction of the anti-mucin core protein (MUC1) antibody MUSE11 variable regions in a bacterial expression system. J. Biochem. 127, 673-679
10. Takemura, S., Asano, R., Tsumoto, K., Ebara, S., Sakurai, N., Katayose, Y., Kodama, H., Yoshida, H., Suzuki, M., Imai, K., Matsuno, S., Kudo, T., and Kumagai, I. (2000) Construction of a diabody (small recombinant bispecific antibody) using a refolding system. Protein Eng. 13, 583-588
11. Takemura, S., Kudo, T., Asano, R., Suzuki, M., Tsumoto, K., Sakurai, N., Katayose, Y., Kodama, H., Yoshida, H., Ebara, S., Saeki, H., Imai, K., Matsuno, S., and Kumagai, I. (2002) A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol. Immunother. 51, 33-44
12. Neumaier, M., Shively, L., Chen, F.S., Gaida, F.J., Ilgen, C., Paxton, R.J., Shively, J.E., and Riggs, A.D. (1990) Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells. Cancer Res. 50, 2128-2134
13. Takemura, S., Asano, R., Tsumoto, K., Arai, T., Sakurai, N., Kodama, H., Yoshida, H., Katayose, Y., Suzuki, M., Matsuno, S., Kudo, T., and Kumagai, I. (2000) Functional Fv fragment of an antibody specific for CD28: Fv-mediated co-stimulation of T cells. FEBS Lett. 476, 266-271
14. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685
15. Kodama, H., Suzuki, M., Katayose, Y., Shinoda, M., Sakurai, N., Takemura, S., Yoshida, H., Saeki, H., Asano, R., Ichiyama, M., Imai, K., Hinoda, Y., Matsuno, S., and Kudo, T. (2002) Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies. Immunol. Lett. 81, 99-106
16. Kodama, H., Suzuki, M., Katayose, Y, Shinoda, M., Sakurai, N., Takemura, S., Yoshida, H., Saeki, H., Ichiyama, M., Tsumoto, K., Asano, R., Kumagai, I., Imai, K., Hinoda, Y., Matsuno, S., and Kudo, T. (2001) Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma. Cancer Immunol. Immunother. 50, 539-548
17. Kipriyanov, S.M., Moldenhauer, G., Martin, A.C., Kupriyanova, O.A., and Little, M. (1997) Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng. 10, 445-453
18. Cochlovius, B., Kipriyanov, S.M., Stassar, M.J., Christ, O., Schuhmacher, J., Strauss, G., Moldenhauer, G., and Little, M. (2000) Treatment of human B cell lymphoma xenografts with a CD3xCD19 diabody and T cells. J. Immunol. 165, 888-895
19. Pimm, M.V., Armitage, N.C., Perkins, A.C., Smith, W., and Baldwin, R.W. (1985) Localization of an anti-CEA monoclonal antibody in colo-rectal carcinoma xenografts. Cancer Immunol. Immunother. 19, 8-17
20. Andrew, S.M., Pimm, M.V., Perkins, A.C., and Baldwin, R.W. (1986) Comparative imaging and biodistribution studies with an anti-CEA monoclonal antibody and its F(ab)2 and Fab fragments in mice with colon carcinoma xenografts. Eur. J. Nucl. Med. 12, 168-175
21. Vuillez, J.P., Moro, D., Brambilla, E., Brichon, P.Y., Ferretti, G., Saccavini, J.C., and Brambilla, C. (1994) Immunoscintigraphy using 111indium-labelled F(ab′)2 fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody for staging of nonsmall cell lung carcinoma. Eur. J. Cancer 30A, 1089-1092
22. Wong, J.Y.C., Chu, D.Z., Yamauchi, D.M., Williams, L.E., Liu, A., Wilczynski, S., Wu, A.M., Shively, J.E., Doroshow, J.H., and Raubitschek, A.A. (2000) A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin. Cancer Res. 6, 3855-3863
23. Kim, J.C., Roh, S.A., Koo, K.H., Ryu, J.H., Hong, H.K., Oh, S.J., Ryu, J.S., Kim, H.J., and Bodmer, W.F. (2002) Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery. Int. J. Cancer 97, 542-547
24. Williams, L.E., Wu, A.M., Yazaki, P.J., Liu, A., Raubitschek, A.A., Shively, J.E., and Wang, J.Y. (2001) Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother. Radiopharm. 16, 25-35
25. Vaquero, C., Sack, M., Schuster, F., Finnern, R., Drossard, J., Schumann, D., Reimann, A., and Fischer, R. (2002) A carcino-embryonic antigen-specific diabody produced in tobacco. FASEB J. 16, 408-410
26. Yazaki, P.J., Shively, L., Clark, C., Cheung, C.W., Le, W., Szpikowska, B., Shively, J.E., Raubitschek, A.A., and Wu, A.M. (2001) Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. J. Immunol. Methods 253, 195-208
27. Holliger, P., Manzke, O., Span, M., Hawkins, R., Fleischmann, B., Qinghua, L., Wolf, J., Diehl, V., Cochet, O., Winter, G., and Bohlen, H. (1999) Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 × anti-CEA bispecific diabodies and B7 × anti-CEA bispecific fusion proteins. Cancer Res. 59, 2909-2916
28. Buchner, J. and Rudolph, R. (1991) Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology 9, 157-162
29. Kiefhaber, T., Rudolph, R., Kohler, H.H., and Buchner, J. (1991) Protein aggregation in vitro and in vivo: a quantitative model of the kinetic competition between folding and aggregation. Biotechnology 9, 825-829
30. Kipriyanov, S.M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.W., Matys, E.R., Little, M. (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 15, 41-56
31. Winter, G., Griffiths, A.D., Hawkins, R.E., and Hoogenboom, H.R. (1994) Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455
32. Wong, C., Waibel, R., Sheets, M., Mach, J.P., and Finnern, R. (2001) Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells. Cancer Immunol. Immunother. 50, 93-101
33. Watanabe, H., Tsumoto, K., Asano, R., Nishimiya, Y., and Kumagai, I. (2002) Selection of human antibody fragments on the basis of stabilization of the variable domain in the presence of target antigens. Biochem. Biophys. Res. Commun. 295, 31-36